CytoDyn Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose Feb 01, 2019 6:00am EST
CytoDyn Names Richard G. Pestell, M.D., Ph.D. as Vice Chairman of its Board of Directors Jan 07, 2019 6:00am EST
CytoDyn’s Prostate Cancer Prognostic Test Demonstrates Substantial Added Value to Gleason Score in Predicting Patient Outcomes Nov 29, 2018 8:58am EST
